URGING THE DEPARTMENT OF HEALTH TO COORDINATE THE STOCKPILING OF A THREE-YEAR SUPPLY OF MIFEPRISTONE.

HR37

HOUSE OF REPRESENTATIVES

H.R. NO.

37

THIRTY-THIRD LEGISLATURE, 2026

STATE OF HAWAII

HOUSE RESOLUTION

URGING THE DEPARTMENT OF HEALTH TO COORDINATE the
STOCKPILING OF A THREE-YEAR SUPPLY OF MIFEPRISTONE
.

����
WHEREAS, recent
developments in the legal landscape of the United States threaten the State's
policy to protect an individual's right to privacy and bodily autonomy; and

����
WHEREAS, Article
I, Sections 3, 5, and 6 of the Hawaii State Constitution have long protected
the bodily autonomy and reproductive rights of the State's residents; and

����
WHEREAS, in
1970, Hawaii became the first state to legalize abortion with the enactment of
Act 1, Session Laws of Hawaii (SLH) 1970; and

����
WHEREAS, in
2006, the State took a constitutionally mandated step to secure the right to
privacy with the enactment of Act 35, SLH 2006, which established that the
State shall not deny or interfere with a pregnant person's right to choose or
obtain an abortion of a nonviable fetus or an abortion that is necessary to
protect a pregnant person's life or health.
�

Act 35 also removed the outdated requirement that an individual who
seeks an abortion must be a Hawaii resident for at least ninety days; and

����
WHEREAS, in
2022, the Supreme Court of the United States held in
Dobbs v. Jackson
Women's Health Organization
, 597 U.S. 215 (2022), that the United States
Constitution does not confer a right to an abortion, overturning
Roe v. Wade
,
410 U.S. 113 (1973) and
Planned Parenthood of Southeastern Pennsylvania v.
Casey
, 505 U.S. 833 (1992); and

����
WHEREAS, some
states have implemented laws and policies imposing civil or criminal liability or
professional discipline in connection with the provision or receipt of, or
assistance with, reproductive health care services, including obtaining or
performing an abortion, outside of these states' borders; and

����
WHEREAS, despite
the State's existing protections for privacy and bodily autonomy, some neighbor
island residents are denied equitable access to reproductive healthcare since
in-person abortion care is only available on the islands of Maui and Oahu; and

����
WHEREAS, sixty-three
percent of abortions in the United States are performed with the administration
of oral abortifacients; and

����
WHEREAS, two
oral abortifacients are commonly used for medical abortions: mifepristone and
misoprostol; and

����
WHEREAS, the
United States Food and Drug Administration may approve changes to the
recommended administration of these medications, and the mifepristone supply
chain may suffer disruptions; and

����
WHEREAS, in
2023, the Department of Health partnered with the Kapiolani Medical Center for
Women and Children to maintain a one-year supply of mifepristone; and

����
WHEREAS,
mifepristone has a shelf-life of five years; and

����
WHEREAS, an
estimated three thousand nine hundred abortions occurred in the State in 2024;
and

����
WHEREAS,
youth and young adults represent a significant portion of those seeking
abortion care in the State, and approximately sixty-four percent of abortions in
Hawaii were sought by individuals under thirty years of age, as of 2022; and

����
WHEREAS, the Hawaii
State Constitution and the State's laws require the State to ensure that the rights
to privacy and to make medical decisions about one's body remain uninfringed; now,
therefore,

����
BE IT
RESOLVED by the House of Representatives of the Thirty-third Legislature of the
State of Hawaii, Regular Session of 2026, that the Department of Health is
urged to coordinate the stockpiling of a three-year supply of mifepristone in
quantities as determined by the Department; and

����
BE IT FURTHER
RESOLVED that a certified copy of this Resolution be transmitted to Director of
Health.

OFFERED BY:

_____________________________

Report Title:
�

Department
of Health; Mifepristone; 3-Year Supply; Stockpile